Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/25/2026 | $35.00 | Buy | BofA Securities |
| 1/29/2026 | $31.00 | Mkt Perform | Citizens JMP |
| 1/8/2026 | $28.00 | Buy | BTIG Research |
| 12/18/2025 | $18.00 | Neutral | Mizuho |
| 8/19/2025 | $36.00 | Overweight | Piper Sandler |
| 5/23/2025 | $8.00 | Underweight → Equal Weight | Wells Fargo |
| 4/17/2025 | $8.00 | Underweight | Wells Fargo |
| 2/6/2025 | $31.00 | Outperform | Wedbush |
BofA Securities initiated coverage of Bicara Therapeutics with a rating of Buy and set a new price target of $35.00
Citizens JMP initiated coverage of Bicara Therapeutics with a rating of Mkt Perform and set a new price target of $31.00
BTIG Research initiated coverage of Bicara Therapeutics with a rating of Buy and set a new price target of $28.00
4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
10-K - Bicara Therapeutics Inc. (0002023658) (Filer)
8-K - Bicara Therapeutics Inc. (0002023658) (Filer)
144 - Bicara Therapeutics Inc. (0002023658) (Subject)
Selected 1500mg weekly of ficerafusp alfa as the optimal dose and initiated Phase 3 of the FORTIFI-HN01 pivotal trial; interim analysis expected mid-2027 Announced development of a less frequent loading and every-three-week maintenance dose of ficerafusp alfa Corporate call to discuss financial results and business updates on Monday, March 30, 2026 at 8:30 a.m. ET BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX) today announced financial results for the fourth quarter and full year ended December 31, 2025 and provided a business update. "Bicara enters the year with exceptional momentum across our clinical, regulatory, and corporate priorities," said Cla
BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that it will report fourth quarter and full year 2025 financial results and business updates before the market opens on Monday, March 30, 2026. Bicara will host a conference call to discuss the financial results and business updates at 8:30 a.m. ET the same day. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and a unique PIN that will allow them to access the call. To acces
BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded an inducement grant on March 2, 2026 to one new employee under Bicara's 2026 Inducement Plan as a material inducement to employment. The employee received a non-qualified stock option to purchase 115,000 shares of Bicara's common stock, par value $0.0001 per share, with an exercise price of $17.59 per share, equal to the closing price of Bicara's common stock as reported by Nasdaq on March 2, 2026. One-fourth of the shares vest on the first annivers
4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
4 - Bicara Therapeutics Inc. (0002023658) (Issuer)
SC 13G - Bicara Therapeutics Inc. (0002023658) (Subject)
SC 13G - Bicara Therapeutics Inc. (0002023658) (Subject)
SC 13D - Bicara Therapeutics Inc. (0002023658) (Subject)
HOUSTON, July 31, 2025 /PRNewswire/ -- The Rice Biotech Launch Pad, a Houston-based accelerator focused on expediting the translation of Rice University's health and medical technology discoveries into cures, announced today the appointment of Carolyn Ng to its external advisory board. A current business unit partner at TPG Life Sciences Innovations, Ng brings expertise in biotech and company building with a track record of guiding early to midstage companies across a wide range of therapeutic areas. "Carolyn's deep understanding of translational science, combined with her passion for fostering high-impact ventures, makes her an ideal addition to the board," said Omid Veiseh, professor of b
CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (NASDAQ:RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, Ph.D., to the Company's Board of Directors, effective June 9, 2025. "It is a privilege to welcome Claire to our Board, where she will draw from her strategic and operational experience in clinical-stage oncology to offer guidance as we prepare to initiate our Phase 3 ReDiscover-2 trial in breast cancer soon," said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics.
BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that it will report fourth quarter and full year 2025 financial results and business updates before the market opens on Monday, March 30, 2026. Bicara will host a conference call to discuss the financial results and business updates at 8:30 a.m. ET the same day. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and a unique PIN that will allow them to access the call. To acces
Phase 1b expansion cohort data evaluating 2000mg of ficerafusp alfa every other week in combination with pembrolizumab in 1L HPV-negative R/M HNSCC patients demonstrate rapid, deep and durable responses with generally well-tolerated safety profile Company plans to develop a loading and every-three-week maintenance regimen for ficerafusp alfa, pending regulatory alignment Company to host conference call and webcast on Friday, February 20, 2026 at 8:30 a.m. ET BOSTON, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today presented
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety profile comparable to 1500mg QW dose, further derisking pivotal FORTIFI-HN01 study interim analysis Totality of data demonstrates that greater TGF-β inhibition, observed at 1500mg of ficerafusp alfa, drives deeper tumor responses that translate to more durable outcomes for patients Pivotal FORTIFI-HN01 optimal dose declaration expected in first quarter 2026 Company to host conference call and webcast today at 9:00 a.m. ET BOSTON, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (NASDAQ:BCAX), a clinical-stage biopharmaceutical company committed to bringing t